#United States #New York #Securities Class Action #Faruqi & Faruqi #REGENXBIO

REGENXBIO Investors: Important Class Action Deadline Ahead

As the deadline for participating in a major securities class action lawsuit approaches, investors in REGENXBIO Inc. (NASDAQ: RGNX) are reminded of their rights and options. A leading national securities law firm, Faruqi & Faruqi, LLP, is actively investigating potential claims against the company, emphasizing the significance of April 14, 2026, as the last date for investors to seek lead plaintiff status.

Background Information

Faruqi & Faruqi has established a strong reputation in the realm of securities litigation, having secured hundreds of millions for investors since its inception in 1995. Recently, the firm has directed its attention to REGENXBIO due to alleged violations of federal securities laws linked to misleading statements made by the company regarding its clinical trials.

The crux of the issue lies in the company's RGX-111 trial, which was put on hold by the U.S. Food and Drug Administration (FDA) following reports of adverse events. On January 28, 2026, REGENXBIO disclosed that the FDA had placed a clinical hold on its gene therapy intended for treating Hurler syndrome (MPS I) after a participant in the study developed a serious health issue. This announcement caused a significant downturn in REGENXBIO's stock price, which dropped by 17.9%.

The Legal Landscape

Under these circumstances, Faruqi & Faruqi is urging investors who felt the impact of these developments—specifically those who acquired REGENXBIO securities from February 9, 2022, to January 27, 2026—to come forward and explore their legal options. Investors can directly contact Josh Wilson, a partner at the firm, to discuss potential claims. Investors have the right to appoint a lead plaintiff who will represent the interests of the class and direct the litigation process. Importantly, participation in the class action is open to all affected investors, and choosing to be a lead plaintiff (or not) does not affect one's ability to recover any financial losses.

Importance of Investor Participation

Engaging with the class action is crucial for all affected investors as it can potentially lead to compensation for financial losses resulting from REGENXBIO's alleged misconduct. The firm encourages anyone with pertinent information—such as whistleblowers, past employees, or shareholders—to engage and share their insights to strengthen the case.

In addition to the ongoing investigation, Faruqi & Faruqi provides up-to-date information through its website and encourages all interested parties to visit Faruqi Law for the latest updates.

Conclusion

As the April 14, 2026 deadline looms, REGENXBIO investors need to evaluate their positions carefully. For those who experienced losses, now is the time to take action. For further inquiries or to engage with the firm's expertise, contact Faruqi & Faruqi at the provided phone numbers. The outcome of the class action could make a significant difference for affected investors during this turbulent time.